+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Genomic Collaboration and Licensing Deals 2016-2023

  • PDF Icon

    Report

  • 450 Pages
  • November 2023
  • Region: Global
  • CurrentPartnering
  • ID: 4636691
Genomic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genomic deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of genomic deals from 2016 to 2023.

The report provides a detailed understanding and analysis of how and why companies enter genomic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 857 genomic deals announced since 2016 including financial terms where available including links to online deal records of actual genomic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of genomic dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in genomic dealmaking since 2016.

Chapter 3 provides an overview of the leading genomic deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in genomic dealmaking with a brief summary followed by a comprehensive listing of genomic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of genomic deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of genomic partnering deals signed and announced since Jan 2016. The chapter is organized by specific genomic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in genomic deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Genomic Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse genomic collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

Genomic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of genomic trends and structure of deals entered into by leading biopharma companies worldwide.

Genomic Collaboration and Licensing Deals includes:

• Trends in genomic dealmaking in the biopharma industry
• Directory of genomic deal records covering pharmaceutical and biotechnology
• The leading genomic deals by value
• Most active genomic licensing dealmakers
Genomic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in genomic dealmaking
2.1. Introduction
2.2. Genomic deals over the years
2.3. Most active genomic dealmakers
2.4. Genomic deals by deal type
2.5. Genomic deals by therapy area
2.6. Genomic deals by industry sector
2.7. Deal terms for genomic deals
2.7.1 Genomic deals headline values
2.7.2 Genomic deal upfront payments
2.7.3 Genomic deal milestone payments
2.7.4 Genomic royalty rates
Chapter 3 - Leading genomic deals
3.1. Introduction
3.2. Top genomic deals by value
Chapter 4 - Most active genomic dealmakers
4.1. Introduction
4.2. Most active genomic dealmakers
4.3. Most active genomic deals company profiles
Chapter 5 - Genomic contracts dealmaking directory
5.1. Introduction
5.2. Genomic contracts dealmaking directory
Chapter 6 - Genomic dealmaking by technology type
Deal directory
Deal directory - Genomic deals by company A-Z
Deal directory - Genomic deals by deal type
Deal directory - Genomic deals by therapy area
Deal type definitions
Table of figures
Figure 1: Genomic deals since 2016
Figure 2: Active genomic dealmaking activity - 2016 - 2023
Figure 3: Genomic deals by deal type since 2016
Figure 4: Genomic deals by therapy area since 2016
Figure 5: Genomic deals by industry sector since 2016
Figure 6: Genomic deals with a headline value
Figure 7: Genomic deals with an upfront value
Figure 8: Genomic deals with a milestone value
Figure 9: Genomic deals with a royalty rate value
Figure 10: Top genomic deals by value since 2016
Figure 11: Most active genomic dealmakers 2016 - 2023
Figure 12: Genomic deals by technology type since 2016

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 1CellBiO
  • 2bPrecise
  • 2seventy bio
  • 3 Sisters Surrogacy
  • 3D Signatures
  • 4baseCare
  • 10X Genomics
  • 14M Genomics
  • 22nd Century
  • 23andMe
  • A*STAR Agency for Science
  • Technology and Research
  • A*STAR Bioinformatics Institute
  • A*STAR Genome Institute of Singapore
  • Abbvie
  • Abcam
  • Abramson Cancer Center
  • Absorption Systems
  • Academia Sinica
  • Accelerated Cure Project for MS
  • Accelerate Technologies
  • Access to Comprehensive Genomic Profiling Coalition
  • Acerta Pharma
  • ACMG Foundation for Genetic and Genomic Medicine
  • ACT Genomics
  • Active Motif
  • ActX
  • Adaptimmune
  • Adaptive Biotechnologies
  • ADInstruments
  • Admera Health
  • Adrestia
  • Advaita
  • ADx Healthcare
  • Aelan Cell Technologies
  • Aevi Genomic Medicine
  • Affymetrix
  • AgBiome
  • Agendia
  • Agilent Technologies
  • Agribody Technologies
  • Agriplex Genomics
  • AiLife Diagnostics
  • Aitbiotech
  • Akadeum Life Sciences
  • AKESOgen
  • Alana Healthcare
  • Albany Molecular Research
  • Alexion Pharmaceuticals
  • AllCells
  • Allele Biotechnology and Pharmaceuticals
  • Almac Diagnostics
  • Alnylam Pharmaceuticals
  • ALS Association
  • ALS Automated Lab Solutions
  • Altor BioScience
  • Alzheimer's Drug Discovery Foundation
  • Amazon Web Services
  • Ambry Genetics
  • America's Choice Provider Network
  • American Physiological Society
  • American Society of Clinical Oncology (ASCO)
  • American Type Culture Collection (ATCC)
  • Amgen
  • Amplicon Express
  • Analytical BioSciences
  • Anam Hospital
  • Angsana Molecular & Diagnostics
  • AnimalBiome
  • Annoroad
  • APG Bio
  • Applied Biosystems
  • Aptorum Group
  • Arbor Biotechnologies
  • Arcadia Biosciences
  • Arc Bio
  • ArcherDX
  • Arcturus Therapeutics
  • Argonaut
  • Arima Genomics
  • Arzeda
  • Aslan Pharma
  • Astellas Pharma
  • AstraZeneca
  • Astrea Forensics
  • Athletigen
  • Atlas Genetics
  • Atlas Genomics
  • ATUM
  • Auria Biobank
  • Avance Biosciences
  • Avera Health
  • Avera Heart Hospital of South Dakota
  • Avvinity Therapeutics
  • Axil Scientific
  • B-MoGen Biotechnologies
  • Baheal Pharmaceutical
  • Bank of America
  • Banner Health
  • BASF
  • Battelle
  • Bayer
  • Bayer CropScience
  • Bayer Healthcare
  • Baylor College of Medicine
  • Baylor Genetics
  • Baylor Miraca Genetics Laboratories
  • BC Platforms
  • BD Biosciences
  • Beckman Coulter
  • Becton Dickinson
  • Beijing Genomics Institute (BGI)
  • Beijing InnoCare Pharma
  • Belgian Society of Medical Oncology
  • Benson Hill Biosystems
  • Berkeley Lights
  • Berry Genomics
  • Beth Israel Deaconess Medical Center
  • BGI
  • BGI Americas
  • Bill and Melinda Gates Foundation
  • Bina Technologies
  • Bio-Rad Laboratories
  • Bio-Techne
  • BioBright
  • Biocartis
  • Biocept
  • Biodesix
  • BioDiscovery
  • BioFire Diagnostics
  • Biogen
  • BioIntelliSense
  • BioIQ
  • BioLegend
  • BioMap
  • BioMarin Pharmaceutical
  • Biomecite Diagnostics
  • Biomedical Advanced Research and Development Authority
  • BioMed X Innovation Center
  • Biomillenia
  • BioNano Genomics
  • BioNova Cientifica
  • BioReference Laboratories
  • BioSkryb
  • Biosplice
  • Biostar
  • BioTheranostics
  • Biotop
  • Blackfynn
  • Blockchain Global
  • Bluebird Bio
  • Blue Cross Blue Shield Association

Methodology

  • The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
  • The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
  • The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
  • The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
  • The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

The publisher provides comprehensive coverage of the following partnering or deal types:

  • Asset purchase
  • Assignment
  • Co-development
  • Co-market
  • Co-promotion
  • Collaborative R&D
  • Contract service
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Royalty financing
  • Settlement
  • Spin out
  • Sub license
  • Supply
  • Termination
  • Warrant

Every deal record is fully categorized and includes the following data, where available:

  • Industry sector
  • Therapy areas
  • Technology type
  • Deal components
  • Financial terms
  • Stage of development
  • Exclusivity
  • Asset type
  • Geographic focus
  • Excluded geography
  • Company press release
  • SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

 

 

Loading
LOADING...